Renta 4 | Grifols has resumed a project it has been working on since 2020 to build a new fractionation plant that will enable it to double its production capacity in Europe. The new factory will be located in Llica del Vall in the province of Barcelona, on land adjacent to its Parets del Valles complex, on an 80,000-square metre site that the company acquired for this purpose in 2018….
Alphavalue/ Divacons | The Catalan plasma derivatives company announced yesterday that, once the period for acceptance of the delisting takeover bid for Biotest has ended, it will control 99.25% of the company. Biotest was delisted on 6 June, according to the information sent to the National Securities Market Commission (CNMV). The delisting offer was accepted by a total of 416,922 ordinary shares of Biotest and 3,002,804 non-voting preferred shares. In…
Banco Sabadell: According to press reports, the U.S. District Court for the Southern District of New York has agreed to investigate Gotham City Research for defamation following the bearish report published on Grifols in January 2024. At the same time, it rejects four of the five charges brought by Grifols (illicit enrichment or interference with business relationships, among others). The court has also explicitly rejected the defendants’ attempt to invoke…
Alphavalue/DIVACONS | The Mason Capital fund, which owns 3.174% of Grifols’ (GRF) class A shares, has expressed its support for the blood products company’s board of directors by backing the list of candidates proposed for election at the next ordinary general shareholders’ meeting, scheduled for Thursday, 5 June. Grifols: Buy, Target Price €14.6/share
Link Securities | Grifols (GRF) informed the National Securities Market Commission (CNMV) that on Tuesday the German federal financial supervisory authority, the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin), approved the publication of the offer document submitted by its subsidiary Grifols Biotest Holdings GmbH with the terms and conditions of the public takeover bid for delisting launched to all shareholders of Biotest AG to acquire all ordinary shares of Biotest, of which Grifols…
Alphavalue/DIVACONS | Brandes Investment Partners has taken advantage of the sharp fall in the stock market value of the Catalan company specialising in plasma products following the tariff crisis to increase its stake in the B shares (non-voting) to 16.4%, with an estimated value of €250 million. This position could be key if Brookfield decides to resume its takeover bid for the company. Grifols shares rose 6.63% on Thursday. Grifols:…
CdM | Grifols shares lost more than 5% on the stock market on Monday. Last Friday, after the market had closed, a report was published by the National Securities Market Commission (CNMV) that was highly critical of the company’s financial management. According to the report sent by the CNMV to the investigating judge in the case, José Luis Calama, and to which “El Mundo” has had access, Grifols’ top management…
Link Securities | Capital Group, historical shareholder of Grifols, faces its exit by placing its stake in the company’s capital below 3%, Expansión newspaper reported yesterday. On 7 February, as recorded in the records of the National Securities Market Commission (CNMV), Capital Group reduced its stake in GRF to 2.902%, from the 3.406% declared on 5 February. Of the 2.9% declared by the fund, 0.45% is also on loan to…
Link Securities | Judge José Luis Calama of the National Court, who is investigating the Grifols case, has asked the National Securities Market Commission (CNMV) to send him a document supporting Gotham’s accusations, arguing that the Catalan pharmaceutical company omitted relevant data in its accounts and provided the market with inaccurate information, as reported yesterday by the digital newspaper ElConfidencial.com. The regulator’s report, which analyses the accusations of the bear…
Link Securities | The Catalan blood products company has received a $21 million grant from the Michael J. Fox Foundation (MJFF) for Parkinson’s Disease Research to identify plasma-based biomarkers that could indicate a person’s likelihood of developing Parkinson’s disease (PD) “many years before” clinical diagnosis. The initiative, dubbed ‘Chronos PD’, could accelerate the discovery of new diagnostic tools, as well as the identification and development of novel therapies that modify…